Financial reports
ARS
2023 FY
Annual report to shareholders
3 Apr 24
10-K
2023 FY
Annual report
26 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
ARS
2022 FY
Annual report to shareholders
30 Mar 23
10-K
2022 FY
Annual report
28 Mar 23
10-Q
2022 Q3
Quarterly report
9 Nov 22
10-Q
2022 Q2
Quarterly report
10 Aug 22
10-Q
2022 Q1
Quarterly report
16 May 22
Current reports
8-K
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
20 Mar 24
8-K
Other Events
30 Jan 24
8-K
Results of Operations and Financial Condition
29 Jan 24
8-K
Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy
25 Jan 24
8-K
Departure of Directors or Certain Officers
8 Jan 24
8-K
Regulation FD Disclosure
8 Jan 24
8-K
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
26 Dec 23
8-K
Vera Therapeutics Provides Business Update and Reports Third Quarter Financial Results
9 Nov 23
8-K
Vera Therapeutics Provides Business Update and Reports Second Quarter Financial Results
10 Aug 23
8-K
Regulation FD Disclosure
20 Jun 23
Registration and prospectus
S-8
Registration of securities for employees
27 Mar 24
424B5
Prospectus supplement for primary offering
30 Jan 24
S-3MEF
Registration of additional securities for an S-3
29 Jan 24
424B5
Prospectus supplement for primary offering
29 Jan 24
S-8
Registration of securities for employees
28 Mar 23
424B5
Prospectus supplement for primary offering
2 Feb 23
424B5
Prospectus supplement for primary offering
1 Feb 23
424B5
Prospectus supplement for primary offering
9 Sep 22
424B5
Prospectus supplement for primary offering
13 Jun 22
424B5
Prospectus supplement for primary offering
13 Jun 22
Other
EFFECT
Notice of effectiveness
14 Jun 22
CORRESP
Correspondence with SEC
9 Jun 22
UPLOAD
Letter from SEC
9 Jun 22
EFFECT
Notice of effectiveness
10 Feb 22
CORRESP
Correspondence with SEC
7 Feb 22
CORRESP
Correspondence with SEC
7 Feb 22
UPLOAD
Letter from SEC
10 Jan 22
EFFECT
Notice of effectiveness
14 May 21
CERT
Certification of approval for exchange listing
13 May 21
SEC STAFF LETTER
SEC staff letter
13 May 21
Ownership
4
Joseph R Young
12 Apr 24
4
Sean Grant
5 Apr 24
4
Sean Grant
5 Apr 24
144
Notice of proposed sale of securities
3 Apr 24
SC 13D/A
Sofinnova Venture Partners X, L.P.
26 Mar 24
4
Maha Katabi
25 Mar 24
144
Notice of proposed sale of securities
21 Mar 24
SC 13D/A
Sofinnova Venture Partners X, L.P.
20 Feb 24
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 24
SC 13G/A
COMMODORE CAPITAL LP
14 Feb 24